Tilray Inc. ($TLRY) Stock Forecast: Up 5.1% Today

What is Tilray Inc.?

Tilray Brands, Inc. (TLRY) is a prominent player in the cannabis industry, with a focus on medical cannabis products and craft beer through its subsidiary SweetWater Brewing Company. TLRY's stock has been experiencing volatility recently, with both bullish and bearish movements.

Why is Tilray Inc. going up?

TLRY stock is up 5.1% on Jan 22, 2026 17:06

• TLRY stock experienced a strong bullish movement recently, possibly due to the launch of SweetWater's new high-ABV brew, Big Trip Double IPA, expanding its product offerings to cater to the craft beer market.
• The establishment of Tilray Medical Italia to strengthen its presence in Italy's medical cannabis market might have also played a role in the positive sentiment, demonstrating the company's dedication to increasing its international ventures.
• Despite facing recent share price challenges and analyst downgrades, the company's undervaluation as pointed out by Simply Wall St's analysis could have attracted value investors, contributing to the bullish movement.
• The bullish momentum in TLRY's stock today is thought to be driven by a combination of product expansion in the craft beer sector, strategic endeavors in the medical cannabis market, and potential value opportunities arising from recent price declines.

TLRY Price Chart

TLRY Technical Analysis

TLRY News

SweetWater Introduces Big Trip Double IPA: A Bold New Craft Beer

SweetWater Brewing Company, a leading craft beer brand and subsidiary of Tilray Brands, Inc., has launched Big Trip Double IPA. This new high-ABV brew, with 9% alcohol, features bright citrus notes and a smooth tropical aroma, expanding SweetWater's popular Daytrip IPA series. It is crafted with a blend of Mosaic, Idaho 7, Sultana, Citra, and El Dorado hops and is available in 19.2 oz and 6-pack 12 oz cans nationwide, targeting the growing popularity of Double IPAs.

https://www.globenewswire.com/news-release/2026/01/22/3223592/0/en/SweetWater-Introduces-Big-Trip-Double-IPA-A-Bold-New-Craft-Beer.html

Tilray Brands, Inc.

Tilray Medical, a division of Tilray Brands, Inc., has launched Tilray Medical Italia to strengthen its presence in Italy's regulated medical cannabis market. This strategic move unifies its European operations and expands its portfolio of authorized medical cannabis products through a partnership with Molteni Farmaceutici. The company aims to support patients, physicians, and healthcare systems with high-quality, authorized medical cannabis while adhering to strict regulatory standards.

https://via.ritzau.dk/pressemeddelelse/14763153/tilray-brands-inc?publisherId=90446&lang=en

Is Tilray Brands (TLRY) Now A Value Opportunity After Recent Share Price Weakness?

Tilray Brands (TLRY) has experienced recent share price weakness, with declines over the past week, month, year-to-date, and the last year. Despite this, Simply Wall St's valuation framework rates TLRY as undervalued on four out of six checks, based on a Discounted Cash Flow (DCF) analysis and a Price-to-Sales (P/S) ratio comparison. The DCF model suggests an intrinsic value of US$9.84 per share, indicating an 11.1% discount from its current price, while its P/S ratio of 1.22x is well below industry averages and Simply Wall St's proprietary 'Fair Ratio' of 1.71x.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tlry/tilray-brands/news/is-tilray-brands-tlry-now-a-value-opportunity-after-recent-s

Tilray Brands (NASDAQ:TLRY) Trading Down 7.4% Following Analyst Downgrade

Tilray Brands (NASDAQ:TLRY) shares dropped 7.4% following Roth Capital's downgrade, lowering their price target from $20 to $10 while maintaining a neutral rating. The company missed EPS estimates last quarter, reporting ($0.41) against an expected ($0.14), despite exceeding revenue forecasts with $217.5M. Analyst consensus on Tilray is currently "Reduce," with an average target price of $13.33.

https://www.marketbeat.com/instant-alerts/tilray-brands-nasdaqtlry-trading-down-74-following-analyst-downgrade-2026-01-20/

Tilray Brands (TLRY): Roth Capital Lowers Price Target to $10

Roth Capital has maintained a Neutral rating for Tilray Brands (TLRY) but significantly lowered its price target by 50% from $20 to $10. This adjustment reflects ongoing evaluations of Tilray's market position and growth prospects within the cannabis industry. Despite this, the average target price from other analysts suggests a potential upside of nearly 40% from the current price, with a consensus "Hold" recommendation.

https://www.gurufocus.com/news/7271144/tilray-brands-tlry-roth-capital-lowers-price-target-to-10-tlry-stock-news

Trending Today

Monero ($XMR) Crypto Forecast: Down 5.4% Today

Tilray Inc. Price History

13.00.2026 - TLRY Stock was down 5.3%

• Despite achieving record revenue and moving to a net cash position, Tilray's stock witnessed a notable bearish trend.
• The market reaction may have been influenced by a substantial EPS miss and deeply negative net margins, sparking investor concerns.
• Analysts recommending exploring alternative investment options despite increased positions from certain institutional investors might have exacerbated the bearish outlook.
• Ongoing worries surrounding operating losses, potential shareholder dilution, and the necessity for Tilray to capitalize on emerging market trends to enhance margins and cash flow likely played a role in the stock's bearish performance.

22.11.2025 - TLRY Stock was down 5.2%

• The bearish movement in Tilray's stock today could be attributed to the company's ongoing financial struggles, lack of earnings, and cash burn.
• Despite recent positive sentiment and stock rises driven by potential easing of marijuana restrictions and strategic developments, the market may be reacting to the underlying financial challenges faced by Tilray.
• The uncertainty surrounding U.S. marijuana reform, particularly the reliance on federal rescheduling rather than outright legalization, might be causing investors to exercise caution and reevaluate their positions in Tilray.

22.11.2025 - TLRY Stock was down 6.0%

• The bearish movement in TLRY stock today could be attributed to the anticipation and uncertainty surrounding the upcoming financial results announcement.
• Comments on Tilray's lack of earnings may have contributed to investor skepticism and selling pressure on the stock.
• Despite the positive news about Tilray's formation of Tilray Medical USA, Inc. to advance its U.S. medical cannabis operations, the overall market sentiment may have been overshadowed by concerns about the company's financial performance and growth strategy.
• The market might be reacting to the realization that Tilray's growth is primarily driven by acquisitions in the alcohol sector rather than its struggling cannabis segment, raising doubts about the company's long-term sustainability.

22.00.2026 - TLRY Stock was up 5.1%

• TLRY stock experienced a strong bullish movement recently, possibly due to the launch of SweetWater's new high-ABV brew, Big Trip Double IPA, expanding its product offerings to cater to the craft beer market.
• The establishment of Tilray Medical Italia to strengthen its presence in Italy's medical cannabis market might have also played a role in the positive sentiment, demonstrating the company's dedication to increasing its international ventures.
• Despite facing recent share price challenges and analyst downgrades, the company's undervaluation as pointed out by Simply Wall St's analysis could have attracted value investors, contributing to the bullish movement.
• The bullish momentum in TLRY's stock today is thought to be driven by a combination of product expansion in the craft beer sector, strategic endeavors in the medical cannabis market, and potential value opportunities arising from recent price declines.

12.00.2026 - TLRY Stock was up 4.9%

• Reported a record Q2 Fiscal 2026 net revenue of $218 million, led by strong performance in international cannabis and Canadian adult-use cannabis segments.
• Transitioned to a net cash position and reaffirmed full-year Adjusted EBITDA guidance, highlighting disciplined execution and a strengthened balance sheet.
• Analysts' opinion that the recent share plunge was overdone aligns with financial results, suggesting potential undervaluation due to underestimation of profit growth in Canadian and international cannabis markets.
• Strategic expansion into the beverage segment, along with readiness to leverage medical cannabis infrastructure in the U.S., positions the company for future growth amidst potential regulatory shifts in the cannabis market.

16.00.2026 - TLRY Stock was down 5.1%

• Tilray's shares declined by 1.9% today, staying close to its 50-day moving average and below its 200-day average, indicating a bearish sentiment in the market.
• The company failed to meet quarterly EPS estimates and revealed negative net margins, resulting in a downgrade to a "strong sell" rating by Zacks Research.
• Despite achieving record Q2 revenues from international operations, Tilray's stock currently holds a Zacks Rank #5 (Strong Sell) primarily due to concerns about its US market prospects.
• Analysts have a cautious stance on Tilray's stock, advising investors to consider other investment opportunities in light of the company's financial performance and market outlook.

15.00.2026 - TLRY Stock was up 5.3%

• Tilray reported record Q2 revenues of $218 million, driven by international operations and distribution, showcasing the company's ability to capture market opportunities.
• Despite a recent EPS miss and negative net margins, the stock saw an increase as investors may be optimistic about the company's long-term growth prospects.
• The focus on higher-margin international markets and new THC beverage offerings indicates Tilray's commitment to diversification and sustainable profitability, which could have positively influenced investor sentiment.
• Analysts suggesting to consider other stocks for better investment opportunities may have created some uncertainty, but the overall market movement reflects confidence in Tilray's strategic direction and potential for future growth.

24.11.2025 - TLRY Stock was down 5.3%

• The upcoming announcement of Tilray Brands' second fiscal quarter financial results has likely created uncertainty and caution among investors, leading to a sell-off of the stock.
• Despite the recent drop, the stock has shown a notable increase over the past month, indicating potential profit-taking by traders.
• The lack of substantial analysis suggests a disconnect between market sentiment and speculative opinions on whether the stock's fall presents a buying opportunity.
• Investors are eagerly awaiting the earnings report, with expectations of a significant increase in EPS, but a slight decrease in revenue compared to the previous year, adding to the volatility surrounding the stock.

06.00.2026 - TLRY Stock was down 5.2%

• The bearish movement in Tilray's stock today can be attributed to multiple factors:
• The formation of a bearish head-and-shoulders pattern, indicating a potential trend reversal and investor caution.
• Heightened volatility ahead of the earnings release, with analysts expecting significant price swings and a projected loss per share.
• The company's expansion into non-alcoholic, cannabis-infused beverages for its "Dry January" campaign might not have been well-received by investors, impacting the stock negatively.
• Investors are closely monitoring Tilray's financial results release on January 9th, potential cannabis reclassification efforts in the US, and the impact of increased competition in the US market for further insights into the stock's performance.

02.00.2026 - TLRY Stock was up 5.6%

• Tilray's stock is struggling to maintain momentum despite recent U.S. regulatory shifts and political support, trading below key technical levels.
• Investor focus is on the upcoming Q2 earnings report, with expectations of a loss per share on revenue. Analysts are looking for signs of financial progress from cost-saving measures and brand integrations.
• The stock's increased attention on social media platforms is sparking discussions about whether TLRY's current mid-single digit trading price reflects a genuine recovery or speculative hype.
• Analysts have a cautiously optimistic stance, considering potential U.S. policy changes and growth in Tilray's alcohol business, balanced against risks like weak cannabis sales and ongoing losses.

29.11.2025 - TLRY Stock was down 5.0%

• Tilray's stock price decreased by 4.2%, closing at $10.085, which was below the broader market performance.
• Analysts have given a consensus "Hold" rating with an average price target of $20, showing caution among investors.
• The drop in stock price may be linked to lower-than-expected performance and uncertainties about the upcoming second fiscal quarter results.
• Despite optimistic prospects for potential cannabis rescheduling and hemp-derived products, investors might be hesitant due to recent underperformance and competition in the AI sector.

29.11.2025 - TLRY Stock was down 5.0%

• Tilray's stock experienced a 4.2% decline in value during mid-day trading, closing at $10.085.
• Analysts have assigned a consensus "Hold" rating to Tilray, with a median price target of $20, indicating a potential upside of 88.49%.
• The bearish movement could be attributed to the cautious sentiment among analysts, despite potential positive developments such as cannabis rescheduling and revised product definitions.
• The upcoming announcement of Tilray's second fiscal quarter results may also be contributing to investor uncertainty and selling pressure on the stock.